Page 32 - Celularity Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

03.02.21 -- Biotech Founders Share Insights On FDA, CMC, And GMP     As you gear up for your first-in-human studies, your chemistry, manufacturing, and controls (CMC) and medical affairs leaders will come together to play principle — and interdependent — roles in the success of those initiatives. On a recent episode of the  Business of Biotech podcast, Dr. Perez, chief medical officer, and Dr. Ihle, VP of CMC and quality, at Bolt Biotherapeutics, Inc., shared their collective advice for emerging biotech leaders who are new to first-in-human studies.  ...

CBRE announced that Jeffrey Dunne, Jeremy Neuer, Steve Bardsley, David Gavin, Gene Pride, Travis Langer and Zach McHale of CBRE’s Institutional Properties group, in partnership with CBRE’s Tom Sullivan, represented an institutional seller in the $46.6 million sale of 170 Park Avenue in Florham Park, New Jersey. 170 Park is fully leased on a long-term basis to Celularity, Inc. and serves as their corporate headquarters, lab, and manufacturing facility. The CBRE team was also responsible for procuring the buyer, JLL Income Property Trust, an institutionally managed daily NAV REIT advised ...

/PRNewswire/ -- JLL Income Property Trust, an institutionally managed daily NAV REIT (NASDAQ: ZIPTAX; ZIPTMX; ZIPIAX; ZIPIMX) with more than $3.5 billion in...

Landcadia Holdings III, Inc. (NASDAQ: LCY) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Landcadia Holdings III, Inc. (NASDAQ: LCY) in connection with the company's proposed merger with HMAN Group Holdings Inc., the parent company of The Hillman Group, Inc. ("Hillman").  Under the terms of the merger agreement, LCY will acquire Hillman through a reverse merger that will result in Hillman becoming a public company traded on the NASDAQ.  If you own LCY shares and wish to discuss this investigation or your rights, p...

Share this article Share this article ResearchAndMarkets.com's offering. Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into a variety of cell types, including but not limited to osteoblasts, chondrocytes, myocytes, and adipocytes. In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic. MSCs are advantageous over other stem cell types for a variety of reasons, including that they are immuno-privileged, making them an advantageous cel...